---
schema_version: "secwatch.filing_event.v1"
accession: "0001837607-25-000092"
form_type: "8-K"
ticker: "AEON"
cik: "0001837607"
company_name: "AEON Biopharma, Inc."
filed_at: "2025-12-15T23:59:59+00:00"
generated_at: "2026-05-16T13:15:12.649530+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.78
calibrated_materiality_score: 0.78
confidence: "high"
source: SEC EDGAR
---

# AEON Biopharma signs definitive exchange with Daewoong; $15M notes swapped for equity, new $1.5M note due 2030

## Summary
- Exchange eliminates >90% of AEON's outstanding debt; Daewoong receives ~23.1M shares, $1.5M new convertible note at 15.79% due Apr 2030.
- Daewoong gets cash-exercise warrant for 8M shares at $1.09392/share, representing up to $8M+ potential proceeds for AEON.
- Exchange remains subject to stockholder vote; closing expected after vote on Jan 21, 2026.
- Daewoong will nominate Seongsoo Park as Class III director at 2026 annual meeting; Park currently on board.

## SEC filing metadata
- accession: 0001837607-25-000092
- form_type: 8-K
- ticker: AEON
- cik: 0001837607
- company_name: AEON Biopharma, Inc.
- filed_at: 2025-12-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.78
- calibrated_materiality_score: 0.78
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1837607/000183760725000092/0001837607-25-000092-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1837607/000183760725000092/aeon-20251215x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001837607-25-000092
- JSON: https://secwatch.observer/filing/0001837607-25-000092.json
- Plain text: https://secwatch.observer/filing/0001837607-25-000092.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.